Genzyme's Gene Therapy for the Treatment of Wet AMD
Description: Genzyme is conducting a Phase I clinical trial of gene therapy for the treatment of wet age-related macular degeneration (AMD). The treatment involves the delivery of a gene that produces a protein which halts the production of vascular endothelial growth factor (VEGF). VEGF is a protein that leads to the proliferation of leaky blood vessels underneath the retina that causes vision loss in wet AMD. An adeno-associated virus is used for gene delivery. As many as 34 participants will be enrolled in the study. Four doses of the treatment are being evaluated.
Trial Status: Recruiting participants.
Partial List of Participation Criteria:
- 50 years of age or older
- Diagnosis of wet age-related macular degeneration
Refer to identifier NCT01024998
Recruiting trial locations include Retinal Consultants of Arizona (Phoenix), Johns Hopkins University School of Medicine (Baltimore), and Ophthalmic Consultants of Boston.
Genzyme’s gene therapy clinical trial listing on ClinicalTrials.gov